Regulatory milestones

Alimera Sciences Inc. (NASDAQ:ALIM) fell $0.39 (14%) to $2.41 on Wednesday after the U.K.'s NICE issued draft guidance recommending against the use of Iluvien fluocinolone acetonide intravitreal implant to treat chronic diabetic macular edema (DME) (see B11).